



Systemic lupus erythematosus (SLE) is a chronic autoimmune 
disease characterized by multisystem inflammation of blood 
vessels and connective tissue.[1] The specific cause of SLE 
is unknown, but multiple factors are associated with the 
development of the disease, namely genetic, ethnic, hormonal, 
and environmental factors.[2]
More than 90% of cases of SLE occur in female, usually 
starting at childbearing age.[3] The male: female ratio before 
puberty is 1:3, but after puberty, it increases to 1:9.[1] The 
manifestations of SLE are mediated by circulating immune 
complexes in various tissues or the direct effects of antibodies 
on cell components.[2] The new classification by the European 
League Against Rheumatism (EULAR) and the American 
College of Rheumatology (ACR) requires an antinuclear 
antibody (ANA) titer of at least 1:80 or an equivalent positive 
test in addition to at least one clinical criterion and 10 or more 
points as diagnostic criteria for SLE.[4]
The course of the disease is milder with higher survival 
rate in persons with isolated skin and musculoskeletal 
involvement than in those with renal disease and central 
nervous system (CNS) disease.[5,6] SLE carries a highly variable 
prognosis in different patients; the natural history of the disease 
ranges from relatively benign disease to rapidly progressive 
and even fatal disease.[7] Delay in diagnosis as well as presence 
of renal or CNS disease is associated with high mortality.
case rePort
A. B was a 13-year-old girl who was referred to our facility 
from a private teaching hospital with 4-month history of 
intermittent cough and fever. She also had progressive weight 
loss with dyspnea, leg swelling, and chest pain. The results of 
the investigations from the referring center are shown in Table 1. 
She had pericardiocentesis that yielded a culture-negative 
effluent; she was being managed for pulmonary tuberculosis 
with effusions and was commenced on antituberculous regimen 
with cefuroxime before she was referred to our facility.
Systemic lupus erythematosus (SLE) is a connective tissue disorder whose manifestations may mimic other common chronic diseases in 
children. In developing countries, its diagnosis is often delayed or missed leading to delay in instituting appropriate treatment and invariably 
high mortality. We report the case of A. B who was a 13-year-old girl referred from a peripheral hospital with chronic cough, weight loss, and 
dyspnea. She had signs of heart failure and developed depression as well as oliguria. The patient also had pleural effusion, but aspirate result 
was negative for Mycobacterium tuberculosis and cytology. She commenced antituberculous drugs and dexamethasone with other supportive 
care but died after 19 days on admission. Serum assay was positive for antinuclear antibody. SLE is a potential masquerader of chronic diseases 
such as tuberculosis. Delay in diagnosis and treatment is associated with poor outcome; hence, there is a need for high index of suspicion for 
early diagnosis with prompt initiation of appropriate treatment.
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At presentation, she was febrile and had clinical features of 
pleural effusion with congestive cardiac failure. She was 
assessed to have disseminated tuberculosis in heart failure, 
to rule out connective tissue disorder. Investigations showed 
elevated erythrocyte sedimentation rate, azotemia, leukocytosis 
with toxic granulation, proteinuria with glycosuria, as 
well as evidence of right-sided pleural with pericardial 
effusion [Table 2 and Figure 1]. She recommenced the 
antituberculous drugs and also ceftriaxone, short course of 
frusemide, fresh frozen plasma, and dexamethasone; she had 
closed tube thoracostomy drainage [Figure 2] with subsequent 
intrapleural injection of streptokinase on the 13th day into 
admission. The patient developed irrational talk, headache, 
and features of depression on admission; she later became 
unconscious and oliguric shortly before demise. She was 
commenced on supportive management for acute kidney injury 
but died 6 h after, although the total duration of admission 
was 19 days. Her autopsy showed widespread fibrotic lesions 
in the lung, but no giant cell or granuloma was seen. She had 
positive ANA test, but the result was retrieved after demise.
dIscussIon
Juvenile SLE is scarcely reported in sub-Saharan Africa 
despite the increasing reports of the adult form. Adelowo 
et al. posited that the juvenile type accounts for about one 
in five cases of SLE in a study from South West Nigeria.[8] 
It accounts for 24.6% of pediatric rheumatic diseases in a 
study by Olaosebikan et al. in Lagos State, Nigeria.[9] Delay 
in diagnosis from symptom onset to diagnosis ranges from 
1 month to 3.3 years.[10] This is due to its similar manifestation 
with other chronic tropical conditions such as tuberculosis.
Pediatric SLE usually presents in postpubescent females.[1] 
The mean ages at lupus diagnosis are 11–12 years.[1,11] There 
is a 24%–56% concordance rate in monozygotic twins, 
compared with a 2%–5% risk in dizygotic twins, suggesting 
genetic tendency.[12] Chronic infections may induce anti-DNA 
antibodies or even lupus-like symptoms, and acute lupus 
flares often follow bacterial infections. Estrogen use in 
postmenopausal women appears to increase the risk of 
developing SLE. Photosensitivity is clearly a precipitant of 
skin disease since ultraviolet light stimulates autoantibody 
production.[13]
Common manifestations of the disease include fatigue, fever, 
weight loss, lymphadenopathy, and hepatosplenomegaly.[1,7] 
Fever may reflect active SLE or infection; patients with SLE 
are considered immunocompromised. Lupus patients may 
be functionally asplenic and may be at risk for encapsulated 
bacterial infections.[7]
Renal disease manifests in about 50% of patients with SLE at 
presentation and is the greatest contributor to morbidity and 
mortality in pediatric SLE population.[1,7] Neuropsychiatric 
disease occurs in up to two-thirds of patients; it is the second 
leading cause of morbidity and mortality in affected population.[1] 
Headache is the most common CNS finding in SLE, occurring 
in 72% of children.[14] Pericarditis is the most common cardiac 
manifestation, while pulmonary involvement may manifest as 
pleuritis, pleural effusion, and pulmonary hypertension[1,7]
ANA is found in 99% of patients with SLE, although it 
may be positive in mixed connective tissue disease and 
dermatomyositis.[1] The anti-dsDNA, on the other hand, is very 
specific for SLE but less sensitive compared to ANA. It may 
be found in >75% of patients with pediatric SLE.[1]
Figure 1: Chest X‑ray showing right‑sided homogenous opacity (pleural 
effusion)
Figure 2: Chest X‑ray after insertion of chest tube at site of pleural effusion 
with cardiomegaly
Table 1: Tests and results from referring center
Tests Results
ESR (mm/h, Westergreen) 70 mm/h
Sputum microscopy Streptococcus pneumonia
Sputum GeneXpert Negative
Echocardiography Moderate pericardial effusion
Abdominal ultrasound Moderate ascites
ESR: Erythrocyte sedimentation rate
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The new diagnostic EULAR/ACR criteria have sensitivity 
of 96.1% and specificity of 93.4%, compared with 
82.8% sensitivity and 93.4% specificity of the 1997 
ACR criteria[4] [Table 3]. Positive ANA result is cardinal 
to making the diagnosis of SLE.[4] In line with the new 
guideline, this index case met more than ten-point criteria 
to diagnose SLE.
Treatment modality is medical and includes the use of 
hydroxychloroquine or nonsteroidal anti-inflammatory 
drugs, whereas severe disease is treated with steroids 
(methylprednisolone and prednisone) or steroid-sparing 
antirheumatic drugs (cyclophosphamide, methotrexate, 
azathioprine, belimumab, and rituximab).[7]
The average 10-year survival rate exceeds 90%;[6] The presence 
of renal or CNS manifestations is associated with poor 
prognosis. The high rate of misdiagnosis or delayed diagnosis 
is probably responsible for high mortality associated with lupus 
in resource-poor settings.[8,11]
conclusIon
SLE is rarely reported in Nigeria owing to frequent 
misdiagnosis. This is because of its similar manifestations with 
other chronic diseases that are endemic in Nigeria and hence 
the need for high index of suspicion for early diagnosis and 
prompt treatment so as to keep the mortality low.
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Mucocutaneous Nonscarring alopecia 2
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